# Who are Samsung Biologics's customers? Who does Samsung Biologics earn revenue from?
Canonical: https://valuechain.wiki/samsung-biologics · Facet: customers · Updated: 2026-09-11T13:43:39.94524+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Samsung Biologics's confirmed revenue counterparties include Bristol-Myers Squibb Company, 리가켐바이오 (ADC 치료제 CDO 위탁개발), 리가켐바이오 (ADC CDO·CMO 수주) plus 4 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 7 revenue edges, backed by 10 dated sources, 2 of them primary filings (as of 2026-09-11).

### 글로벌 빅파마 (CMO 위탁생산, 지역 익명) (high)
- metric: Amount 2,074,700,000,000원 · 최대 CMO 계약(미국 제약사) · region-anonymized; $21.4B cumulative
- note: Contract-manufactures biologics for global pharma; counterparties are region-only disclosed under confidentiality (with set reveal dates). 2024-25 megadeals: US pharma at KRW 2.07tn, 1.80tn and 1.46tn, an Asia pharma at KRW 1.70tn, a Europe pharma at KRW 0.93tn. Revenue split Europe 52%, US 38%. Cumulative orders ~$21.4B (112 CMO, 169 CDO).
- [confirms] FSS DART (KO, filing, published 2026-06-22) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260622800686: "CMO firm value USD 190.5M (~KRW 216bn), counterparty 'an Asia-region pharma' (confidential, reveal 2037), term to 2037-12-31."
- [confirms] FSS DART (KO, filing, published 2026-05-15) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515001658: "US-pharma CMO deals of KRW 2.07tn, 1.80tn, 1.46tn; Asia-pharma KRW 1.70tn; Europe-pharma KRW 0.93tn. Revenue Europe 52%, US 38%."
- [confirms] Reuters (EN, news, published 2026-01-22) https://www.reuters.com/business/healthcare-pharmaceuticals/samsung-biologics-cdmo-2025: "Samsung Biologics reported record CDMO orders and spun off Bioepis for pure-play CDMO focus."
- [confirms] KPA News (KO, news, published 2026-01-15) https://www.kpanews.co.kr/news/articleView.html?idxno=530934: "Cumulative $21.4B across 112 CMO and 169 CDO deals."

### 글로벌 빅파마 (CMO·CDO 위탁생산) (high)
- metric: Amount $21.4B · 누적 수주 · 112 CMO, 169 CDO deals
- note: The world's largest biologics CDMO (784,000L with plant 5 online): 112 CMO and 169 CDO cumulative deals worth $21.4B; record KRW 6.6tn of 2025 orders, guiding 15-20% revenue growth.
- [confirms] KPA News (KO, news, published 2026-01-15) https://www.kpanews.co.kr/news/articleView.html?idxno=530934: "Cumulative $21.4B across 112 CMO and 169 CDO deals; record KRW 6.6tn 2025 orders."

### 브리스톨 마이어스 스퀴브 (high)  → /bristol-myers-squibb.md
- metric: Contract value $242M · 2023-2030 · Value of the BMS antibody cancer drug contract manufacturing agreement announced in 2023
- note: Samsung Biologics manufactures drug substance for a commercial BMS antibody cancer medicine under a contract announced in 2023 and valued at $242 million through 2030.
- [confirms] Yonhap News Agency (KO, news, published 2023-09-18) https://www.yna.co.kr/view/AKR20230918037800017: "Samsung Biologics disclosed a $242 million contract manufacturing agreement with BMS."
- [confirms] Samsung Biologics (EN, ir, published 2023-09-18) https://samsungbiologics.com/media/company-news/samsung-biologics-announces-expanded-strategic-agreement-with-bristol-myers-squibb: "Samsung Biologics will provide drug substance manufacturing for an antibody cancer drug substance at Plant 4."

### 리가켐바이오 (ADC 치료제 CDO 위탁개발) (high)  → /ligachem-biosciences.md
- note: Signed a CDO contract to develop LigaChem Biosciences' ADC therapeutic - a flagship CDO service engagement.
- [confirms] FSS DART (KO, filing, published 2026-05-15) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515001658: "Signed a CDO deal for LigaChem Biosciences' ADC therapeutic."

### 리가켐바이오 (ADC CDO·CMO 수주) (high)  → /ligachem-biosciences.md
- note: Won ADC development and manufacturing mandates from LigaChem Biosciences (Feb 2024 CDO deal, Songdo ADC facility).
- [confirms] Edaily Pharm (KO, news, published 2024-06-17) https://pharm.edaily.co.kr/news/read?newsId=03722806642038048: "Samsung Biologics secured LigaChem's ADC development and manufacturing."

### 화이자 (mid)  → /pfizer.md
- metric: Contract value ₩922.8B · 2023-06-30/2029-12-31 · Value of the Pfizer contract manufacturing supply agreement disclosed in July 2023
- note: Samsung Biologics manufactures for Pfizer under contract. A securities research report details the value and term, running to the end of 2029, of the agreement disclosed in July 2023.
- [confirms] Hyundai Motor Securities (KO, research, published 2024-01-12) https://www.hmsec.com/documents/research/20240112070425593_ko.pdf: "The report lists the July 3, 2023 Pfizer contract at KRW 922.75 billion, ending December 31, 2029."
- [confirms] Samsung Biologics (KO, ir, published 2023-07-04) https://samsungbiologics.com/kr/media/company-news/samsung-biologics-unveils-$-897-mln-manufacturing-deals-for-pfizer: "Samsung Biologics said it won Pfizer contract manufacturing orders worth KRW 1.2 trillion."

### 길리어드 사이언스 (mid)  → /gilead-sciences.md
- metric: Contract value ₩300.5B · 계약 누계 공개액 · Samsung Biologics contract-manufacturing value for Gilead, formerly Immunomedics
- note: Samsung Biologics manufactures for Gilead under contract. A Hana Securities review of Samsung Biologics' supply contracts lists Gilead as a customer, recording a KRW 300.5 billion contract and the 2021 counterparty change and volume increase.
- [confirms] Hana Securities (KO, research, published 2023-01-30) https://www.hanaw.com/download/research/FileServer/WEB/industry/enterprise/2023/01/29/SamsungBiologics_230130.pdf: "The supply-contract table lists Gilead, formerly Immunomedics, with a KRW 300.5 billion contract-manufacturing agreement and notes increased volume."

Reverse side: https://valuechain.wiki/samsung-biologics/suppliers.md · Ripple: https://valuechain.wiki/samsung-biologics/ripple.md

---
Full node: https://valuechain.wiki/samsung-biologics.md · JSON: https://valuechain.wiki/samsung-biologics.json